Results
What have we achieved so far in advancing treatments for rare eye diseases in Europe? Our recent publications share important initial findings.
No time to dive into each publication in detail? We have distilled the key insights from each study in our summaries below, tackling these 4 questions:
- What was the purpose of this study?
- What did the researchers do?
- What did they find?
- What are the main implications?
Dive in and get up to speed with our latest insights.
22 July 2025
New study: Enhancing Immune Modulation with “trained” MSC-EVs
In this study, the Restore Vision team at Galway explored whether EVs from MSCs that were specially “trained” using two immune-related proteins – TGF-β1 and IFN-γ – could more effectively regulate the immune system than EVs from untrained cells.
Read more
08 May 2025
New study: mineralocorticoid receptor antagonism improves corneal integrity in a rat model of limbal stem cell deficiency
In this new study, our team at INSERM, explored whether mineralocorticoid receptor antagonists (MRAs)—commonly used for heart and kidney conditions—could aid corneal repair in limbal stem cell deficiency (LSCD), a rare and difficult-to-treat eye disease.
Read more
01 May 2025
New study: the role of Mesenchymal Stromal Cells and Apoptotic Bodies in immune regulation
Research has shown that MSC-derived ApoBDs can help regulate the immune system, however they have not been studied as much as smaller extracellular vesicles. To fill in the gap, our team at Galway conducted a study to explore the therapeutic potential of large and small ApoBDs.
Read more
06 February 2025
Healing the cornea: the therapeutic potential of Mesenchymal Stromal Cells and their Extracellular Vesicles
In this new article, our team at the University of Galway reviewed and analysed current research on the use of MSCs and MSC-EVs in treating corneal diseases.
Read more
30 January 2025
New article: Are inactive ingredients in eye drops safe? A closer look at excipients safety, function an regulation.
Restore Vision has conducted the first comprehensive review of FDA-approved excipients in ophthalmic medications, examining their roles, safety, and the regulatory pathways required for approval for human use.
Read more
12 May 2024
Antisense eye drops only or combined with fine needle diathermy could be used to regress corneal neovascularization in mice – study by UKK
At the recent ARVO meeting, Wei Zhang presented the latest findings from the University of Cologne on a new treatment to regress corneal neovascularization in mice
Read more
12 May 2024
Genetic research shows promise for developing a treatment for the rare eye disease Aniridia – Study by UKK
At the recent ARVO meeting, Karina Hadriaan presented the latest findings from the University of Cologne on a new treatment to regress corneal neovascularization in mice
Read more
12 May 2024
Effectiveness of a new eyedrop in healing wounds on the cornea in rats – Study by INSERM
At the recent ARVO meeting, Daniela Braz presented the latest findings from INSERM on the development of a new eye drop to treat cornea wounds in mice.
Read more
12 May 2024
Exploring the use of spironolactone to treat diseases of the cornea – Study by INSERM
At the recent ARVO meeting, Raquel Gregorio presented the latest findings from INSERM on the use of spironolactone for treating corneal diseases.
Read more
11 May 2024
A novel combination treatment offers promise for corneal vessel regression and longer graft survival – Study by UKK
At the recent ARVO meeting, Meert Mestanoglu presented UKK’s ongoing research on a novel combination treatment for corneal vessel regression.
Read more